Clinical Protocol Sample Clauses

Clinical Protocol. (a) NCI will facilitate the solicitation and receipt of ▇▇▇▇ for clinical research, contemplating the use of Collaborator’s Formulary Agents. NCI will require potential Sponsors to complete a “Letter of Intent” (“LOI”). NCI will provide Collaborator with a copy of any LOI submitted which requests use of Collaborator’s Formulary Agents, which contains a summary of the draft clinical protocol including the proposed statistical analysis plan for the Study and, estimated funding from the Collaborator to support the Study. (b) Within 60 days of receipt of a Letter of Intent from NCI, Collaborator shall provide a written notice to IC whether or not it approves the LOI. Acceptance of an LOI shall be Collaborator’s sole discretion. • If Collaborator notifies NCI of its rejection of the LOI within such 60-day period, then neither Party shall have any obligations to the other with respect to the proposed Study or any drug supply in respect of such Study. • If Collaborator notifies NCI within such 60-day period that it approves the LOI with a signed drug approval form, the Approved Investigator will draft and submit a full clinical Protocol(s) for approval by Collaborator. • Following the LOI approval, the Parties (or their respective designated Affiliate) will, as soon as reasonably practicable following such notification, arrange communications between PMB staff and Collaborator supply personnel to discuss logistics. • Any changes to the Protocol shall require Collaborator’s prior written consent. Any such proposed changes will be sent in writing to Collaborator by Approved Investigator.
View SourceView Similar (3)
Clinical Protocol. Clinical protocol proposals for each study within the scope of the CRADA Research Plan will be solicited from selected intramural and extramural clinical investigators. Each clinical protocol should describe in detail the research to be conducted and must DC submitted to the PRC for approval prior to implementation. Each clinical protocol received by NCI will be forwarded to Collaborator for review and comment approximately two weeks before it is reviewed by the PRC. Comments from Collaborator received by CTEP before the PRC meeting will be discussed by the PRC, will be given due consideration, and will be incorporated into the protocol, absent good cause. Comments from either Collaborator or the CTEP staff that are agreed upon in the PRC meeting will DC formatted as a consensus review, which is returned to the investigator for necessary and/or suggested changes before the protocol can DC given Final approval and submitted to the FDA. A copy of the final approved protocol will be forwarded to Collaborator at the same time as it is submitted to the FDA. NCI protocol #00-C-0050 (P-92), entitled ‘Phase 3 Randomized Study of Autologous Lvmphoma Derived Idiotype Specific Vaccination Plus Sargramostim (GM-CSF) in Patients with Indolent Follicular Lvmphoma in First Complete Remission’ will be transferred to Collaborator upon FDA approval of Collaborator’s IND application.
View SourceView Similar (2)
Clinical Protocol. Biodel shall furnish to Aegis a copy of the clinical protocol and the related patient informed consent form for any clinical trial study, which involves an Enhancement Agent or the Aegis Technology; and Aegis shall be entitled to share such documents with the Aegis insurance carriers to the extent required to comply with its contractual obligations to such entities. Aegis agrees that any personally identifiable information or protected health information, which comes into Aegis’ possession under this License Agreement will be protected and acted on in accordance with applicable data protection legislation, such as the Health Insurance Portability and Accountability Act of 1996 as well as all other applicable laws and regulations.
View Source
Clinical Protocol. First the GH secretory reserve was assessed by three stimulation tests in addition to the ITT, and subsequently spontaneous GH secretion was measured during 24h with blood sampling intervals of 10 minutes. The GH stimulation tests were carried out in random order on separate days (during a two- week period) in the fasting condition. The following tests were performed: the GHRH test (Fer- ring, Hoofddorp, The Netherlands: 1 μg/kg body weight by i.v. bolus injection, blood samples drawn at 0, 20, 30, 45, 60 and 90 min), the l-arginine infusion test (500 mg/kg body weight with a maximum of 30 g, infusion during 30 minutes, blood samples drawn at 0, 30, 45, 60, 90 and 120 min), and the combined GHRH-arginine test as an i.v. bolus injection of GHRH (1 μg/ kg body weight) after which l-arginine (500 mg/kg body weight with a maximum of 30 g) was infused during 30 minutes, blood samples drawn at 0, 30, 45, 60, 90 and 120 min. The peak serum response of GH was used as the primary variable for analysis of stimulation tests. For the 24h sampling study, the patients were admitted to the Clinical Research Center in the morning. An indwelling i.v. cannula was inserted in a forearm vein at least 60 min before sampling began. Blood samples were withdrawn at 10 min. intervals for 24h, starting at 09.00h. A slow infusion of 0.9% NaCl and heparin (1 U/ml) was used to maintain patency of the i.v. catheter. The subjects were not allowed to sleep during the daytime. Meals were served at 09.00, 12.30 and 17.30h. Lights were turned off between 22.00-24.00h. Plasma samples for GH measurements were collected, centrifuged at 4°C for 7 minutes, and stored at –20°C until later analysis. Assays GH concentrations in the samples of the stimulation tests were measured by time resolved immunofluorometric assay (Wallac, Inc, Turku, Finland). Reference values, listed in the tables and main text were obtained with the same assay. Human biosynthetic GH (Pharmacia and Upjohn, Inc, Uppsala, Sweden) was used as standard, calibrated against WHO-IRP 80-505 and the detection limit of this GH assay is 0.01 μg/l with an interassay coefficient of variation of 1.6-8.4%, between 0.1 and 15 μg/l (1 μg/l = 2.6 mU/l). GH concentration in the serum samples of 24h profiles of the patients in this study were measured with the more sensitive automatic immunochemiluminescence assay (Nichols Diagnostics Institute, San Clemente, CA), using 22 kDa rhGH as standard. Cross reactivity with 20kDa GH was 30%. Assay sens...
View Source
Clinical Protocol. Effective April 29, 2004, NCI protocol #00-C-0050 (P-92), entitled ‘Phase 3 Randomized Study of Autologous Lymphoma Derived Idiotype Specific Vaccination Plus Sargramostim (GM-CSF) in Patients with Indolent Follicular Lymphoma in First Complete Remission’ will be conducted under Collaborator’s IND application # 5427.
View Source
Clinical Protocol. IC will facilitate the solicitation and receipt of proposals for clinical research, contemplating the use of Collaborator’s Formulary Agents. IC will require potential Sponsors to complete a “Letter of Intent” (“LOI”). IC will provide Collaborator with a copy of any LOI submitted which requests use of Collaborator’s Formulary Agents, which contains a summary of the draft clinical protocol including the proposed statistical analysis plan for the Study, and estimated funding from the Collaborator to support the Study.
View Source

Related to Clinical Protocol

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and, for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes materially call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.